Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Appili Therapeutics Inc (OP: APLIF )

0.0255 -0.0055 (-17.74%)
Streaming Delayed Price Updated: 1:48 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Appili Therapeutics Inc

< Previous 1 2 Next >
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
From Aditxt, Inc.
Via Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
From Appili Therapeutics
Via Business Wire
Appili Therapeutics Presents at the 10th International Tularemia Conference
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics – Press Release Correction
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
From Appili Therapeutics Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.